Compare Panacea Biotech with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs WOCKHARDT - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH WOCKHARDT PANACEA BIOTECH/
WOCKHARDT
 
P/E (TTM) x 11.3 -21.0 - View Chart
P/BV x 2.4 1.1 215.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   WOCKHARDT
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
WOCKHARDT
Mar-18
PANACEA BIOTECH/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs3541,012 34.9%   
Low Rs138532 26.0%   
Sales per share (Unadj.) Rs74.6355.9 21.0%  
Earnings per share (Unadj.) Rs6.7-60.3 -11.1%  
Cash flow per share (Unadj.) Rs15.5-46.8 -33.1%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs57.2257.8 22.2%  
Shares outstanding (eoy) m61.25110.63 55.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.2 152.1%   
Avg P/E ratio x36.8-12.8 -287.6%  
P/CF ratio (eoy) x15.9-16.5 -96.2%  
Price / Book Value ratio x4.33.0 143.6%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m15,06185,379 17.6%   
No. of employees `0002.36.3 37.0%   
Total wages/salary Rs m1,4719,371 15.7%   
Avg. sales/employee Rs Th1,973.66,295.0 31.4%   
Avg. wages/employee Rs Th635.61,498.3 42.4%   
Avg. net profit/employee Rs Th176.8-1,066.3 -16.6%   
INCOME DATA
Net Sales Rs m4,56739,369 11.6%  
Other income Rs m451,202 3.7%   
Total revenues Rs m4,61240,571 11.4%   
Gross profit Rs m2,03018 11,091.3%  
Depreciation Rs m5401,495 36.1%   
Interest Rs m1,0482,555 41.0%   
Profit before tax Rs m486-2,830 -17.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m77257 30.0%   
Profit after tax Rs m409-6,669 -6.1%  
Gross profit margin %44.40 95,610.2%  
Effective tax rate %15.9-9.1 -174.6%   
Net profit margin %9.0-16.9 -52.9%  
BALANCE SHEET DATA
Current assets Rs m2,41533,796 7.1%   
Current liabilities Rs m9,07726,917 33.7%   
Net working cap to sales %-145.917.5 -835.0%  
Current ratio x0.31.3 21.2%  
Inventory Days Days6579 82.0%  
Debtors Days Days7189 79.5%  
Net fixed assets Rs m8,33339,664 21.0%   
Share capital Rs m61553 11.1%   
"Free" reserves Rs m3,44327,968 12.3%   
Net worth Rs m3,50428,522 12.3%   
Long term debt Rs m46121,731 2.1%   
Total assets Rs m13,75581,620 16.9%  
Interest coverage x1.5-0.1 -1,361.4%   
Debt to equity ratio x0.10.8 17.3%  
Sales to assets ratio x0.30.5 68.8%   
Return on assets %10.6-5.0 -210.2%  
Return on equity %11.7-23.4 -49.9%  
Return on capital %38.7-7.7 -504.3%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,2039,807 12.3%   
Fx outflow Rs m4671,789 26.1%   
Net fx Rs m7368,019 9.2%   
CASH FLOW
From Operations Rs m1,049684 153.2%  
From Investments Rs m-546,302 -0.8%  
From Financial Activity Rs m-1,011-7,695 13.1%  
Net Cashflow Rs m-20-664 3.0%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 2.3 26.1%  
FIIs % 1.3 7.7 16.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 23.6 15.4 153.2%  
Shareholders   10,259 67,757 15.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   BIOCON   CADILA HEALTHCARE  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 11, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS